Tenaya Therapeutics
TNYA | NASDAQ
$0.39
-$0.13 (-25.14%)
At close: Oct 14, 2026, 4:00 PM ET
Tenaya Therapeutics Company Profile
Company profile explainedCompany Profile
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Faraz Ali | President, CEO & Director |
| Kee-Hong Kim | Chief Technology Officer |
| Benoit G. Bruneau | Scientific Founder |
| Bruce R. Conklin | Scientific Founder |
| Deepak Srivastava | Scientific Founder, Chairman of Scientific Advisory Board & Director |
| Eric Hyllengren | CFO & Principal Accounting Officer |
| Eric N. Olson | Scientific Founder & Member of Scientific Advisory Board |
| Saptarsi Haldar | Scientific Founder |
| Sheng Ding | Scientific Founder |
| Whittemore G. Tingley | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 11, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
| Aug 24, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 17, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 05, 2026 | S-8 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 3 | Filing |
| Jul 14, 2026 | 4 | Filing |
Tenaya Therapeutics
| Country | United States |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Faraz Ali |
Contact Details
171 Oyster Point Boulevard South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | TNYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001858848 |
| CUSIP Number | 87990A106 |
| ISIN Number | US87990A1060 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove TNYA